Ehab L. Atallah, MD, on Heterogeneity in CML Treatment: Focus on Monitoring Response

Posted: Tuesday, July 7, 2020

Ehab L. Atallah, MD, of the Medical College of Wisconsin, talks about how oncology practices in the United States are discontinuing tyrosine kinase inhibitor treatment for patients with chronic myeloid leukemia in chronic phase without adequate tools to monitor response. He advocates broader application of guidelines, especially in community-based practices, to improve long-term treatment-free remission rates.

---